이중 에너지 X선 흡수 측정법(DXA) : 시장 점유율 분석, 업계 동향 및 통계, 성장 예측(2026-2031년)

According to Mordor Intelligence, the dual-energy x-ray absorptiometry market size is projected to expand from USD 0.81 billion in 2025 and USD 0.86 billion in 2026 to USD 1.18 billion by 2031, registering a CAGR of 6.39% between 2026 to 2031.

This report is Segmented by Product Type (Central/Axial DEXA, and More), Technology (Fan-Beam, Pencil-Beam), Application (Osteoporosis Diagnosis, and More), End User (Hospitals, Diagnostic/Imaging Centers, Specialty Clinics), and Geography (North America, Europe, Asia-Pacific, Middle East & Africa, South America). The Market Forecasts are Provided in Terms of Value (USD).

Global Dual-energy X-ray Absorptiometry (DEXA) Market Trends and Insights

Aging Population and Rising Fragility-Fracture Burden

People aged 65+ climbed to 761 million in 2024 and will approach 994 million by 2030, with East Asia and Southern Europe aging the fastest . Japan already records 180,000 hip fractures a year, costing JPY 1.2 trillion (USD 8.1 billion) in direct care. South Korea saw a 14% fracture rise in fractures among women 70+ between 2020 and 2024. The WHO lists fragility fractures as the top cause of disability-adjusted life-years lost for women over 60 in high-income countries. This demographic wave ensures a persistent baseline for baseline and follow-up Dual-energy X-ray Absorptiometry market demand.

Guideline-Backed Screening and Payer Coverage Expand Testable Populations

The 2025 USPSTF update added 12 million U.S. women aged 50-64 with elevated FRAX scores to screening eligibility . CMS kept national payment at USD 127.42 per central scan in 2025, protecting revenue stability. China's National Health Commission bundled bone-density screening into its Essential Public Health Services for urban women 65+ in 2025, targeting 40 million beneficiaries by 2028. Australia similarly extended rebates to older men with prior fractures in 2024. These policies shift DEXA from optional to protocol-driven imaging, anchoring volume growth.

Reimbursement Variability and Declining In-Office Rates Depress Utilization

The 2025 Medicare schedule cut non-facility payment 3.2%, dragging aggregate office margins 11% below 2020 levels. Private payers diverge: Cigna pays 110% of Medicare in-network but only 85% out-of-network, skewing geographic access. Blue Cross NC tightened prior authorization in 2024, slicing local scan volume 7% in six months. Higher hospital facility fees shift the cost burden to patients on high-deductible plans, curbing elective tests. Rural centers with limited throughput struggle to recover capital on USD 80,000-150,000 units, slowing fleet renewal.

Other drivers and restraints analyzed in the detailed report include:

1. DEXA As Clinical Gold Standard With Add-On TBS And AI Analytics
2. GLP-1 Weight-Loss Programs Spur DXA Body-Composition Monitoring
3. Persistent Post-Fracture Care Gap and Low Screening Adherence

For complete list of drivers and restraints, kindly check the Table Of Contents.

Segment Analysis

Central platforms generated 61.30% of 2025 revenue and are poised for a 7.95% CAGR through 2031, underpinned by hip and spine metrics that remain the diagnostic gold standard. This segment undergirds the Dual-energy X-ray Absorptiometry market size because payers reimburse central scans at USD 127.42, roughly triple peripheral rates, and because AI-driven vertebral-fracture assessment and TBS analytics are available only on central hardware. Lifecycle services, software subscriptions, phantoms, and service contracts, contribute another quarter of revenue, raising total return on investment.

Peripheral devices occupy value niches in rural screening and occupational health. Units priced under USD 25,000 attract small clinics, but Medicare's USD 37.26 payment under CPT 77081 constrains profitability. Clinical guidelines continue to advise confirmatory central imaging for treatment decisions, limiting peripheral uptake beyond triage programs. As reimbursement favors comprehensive assessment and body-composition analytics, central systems will retain the bulk of the Dual-energy X-ray Absorptiometry market share.

Fan-beam systems held 65.98% of 2025 revenue and are expected to outpace the overall Dual-energy X-ray Absorptiometry market at an 8.16% CAGR to 2031. Scan times under two minutes boost patient throughput and cut motion artifacts, critical for pediatric and bariatric cohorts. Narrow-angle fan beams now deliver radiation doses of just 0.4 μSv per whole-body exam, well below regulatory thresholds.

Pencil-beam technology persists where capital budgets are tight. Systems costing below USD 50,000 remain common in Latin America and Southeast Asia, yet their larger pixel size hampers vertebral morphometry and VFA analytics. The International Society for Clinical Densitometry cautions that pencil-beam and fan-beam data are not interchangeable, driving integrated networks toward fleet standardization on fan-beam platforms.

Geography Analysis

North America accounted for 42.17% of 2025 revenue. The 2025 USPSTF expansion and steady CMS rates maintain scan volume, yet office reimbursements dropped 3.2% year on year, pushing providers to hospital outpatient departments. Canada reimburses seniors province-wide, but utilization lags guideline targets, and Mexico's coverage outside metros remains sparse.

Asia-Pacific is forecast to grow 8.44% through 2031, the fastest regional CAGR. China's 2025 public-health mandate will install roughly 3,000 additional central units by 2028. Japan subsidizes prefectural screening to contain JPY 1.2 trillion annual fracture costs. India's vast unmet need and low penetration represent upside once unit pricing falls below USD 40,000. Europe shows mixed maturity. The U.K. operates fracture liaison services in 62% of trusts, yet still scans only 28 women per 1,000 over 65 years old. Germany's 2025 guideline update could add 2.5 million eligible women. France now reimburses TBS, an early adopter move. Budget limits restrain Italy and Spain, while GCC states mandate screening for older women, bolstering unit sales.

1. DMS Imaging
2. FUJIFILM
3. GE Healthcare
4. Guangzhou Yueshen
5. Mednova
6. Hologic
7. MEDIKORS Co., Ltd.
8. Medilink (France)
9. Medonica Co., Ltd.
10. Osteometer Meditech A/S
11. OsteoSys Co., Ltd.
12. Pinyuan Medical (Jiangsu) Co., Ltd.
13. Shenzhen XRAY Electric Co., Ltd.
14. Swissray International (Norland)
15. XinGaoyi Medical Equipment Co., Ltd.

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support

TABLE OF CONTENTS

1 Introduction

• 1.1 Study Assumptions & Market Definition
• 1.2 Scope of the Study

2 Research Methodology

3 Executive Summary

4 Market Landscape

• 4.1 Market Overview
• 4.2 Market Drivers
  • 4.2.1 Aging Population and Rising Fragility-Fracture Burden
  • 4.2.2 Guideline-Backed Screening and Payer Coverage Expand Testable Populations
  • 4.2.3 DEXA as The Clinical Gold Standard with Add-On TBS And AI Analytics
  • 4.2.4 GLP-1 Weight-Loss Programs Spur DXA Body-Composition Monitoring
  • 4.2.5 Opportunistic CT Case-Finding Channels Referrals to Confirmatory DEXA
• 4.3 Market Restraints
  • 4.3.1 Reimbursement Variability and Declining In-Office Rates Depress Utilization
  • 4.3.2 Persistent Post-Fracture Care Gap and Low Screening Adherence
  • 4.3.3 Substitution Risk from Opportunistic CT/QCT And QUS In Select Settings
  • 4.3.4 Cross-Vendor Standardization Issues and Capital/Space Constraints
• 4.4 Supply Chain Analysis
• 4.5 Regulatory Landscape
• 4.6 Technological Outlook
• 4.7 Porter's Five Forces Analysis
  • 4.7.1 Threat of New Entrants
  • 4.7.2 Bargaining Power of Suppliers
  • 4.7.3 Bargaining Power of Buyers
  • 4.7.4 Threat of Substitutes
  • 4.7.5 Competitive Rivalry

5 Market Size & Growth Forecasts (Value, USD)

• 5.1 By Product Type
  • 5.1.1 Central/Axial DEXA
  • 5.1.2 Peripheral DEXA
• 5.2 By Technology
  • 5.2.1 Fan-beam
  • 5.2.2 Pencil-beam
• 5.3 By Application
  • 5.3.1 Osteoporosis diagnosis
  • 5.3.2 Body composition analysis
  • 5.3.3 Vertebral fracture assessment (VFA)
• 5.4 By End User
  • 5.4.1 Hospitals
  • 5.4.2 Diagnostic/Imaging Centers
  • 5.4.3 Specialty Clinics (Orthopedics/Endocrinology/Rheumatology)
• 5.5 By Geography
  • 5.5.1 North America
    • 5.5.1.1 United States
    • 5.5.1.2 Canada
    • 5.5.1.3 Mexico
  • 5.5.2 Europe
    • 5.5.2.1 Germany
    • 5.5.2.2 United Kingdom
    • 5.5.2.3 France
    • 5.5.2.4 Italy
    • 5.5.2.5 Spain
    • 5.5.2.6 Rest of Europe
  • 5.5.3 Asia-Pacific
    • 5.5.3.1 China
    • 5.5.3.2 India
    • 5.5.3.3 Japan
    • 5.5.3.4 South Korea
    • 5.5.3.5 Australia
    • 5.5.3.6 Rest of Asia-Pacific
  • 5.5.4 Middle East and Africa
    • 5.5.4.1 GCC
    • 5.5.4.2 South Africa
    • 5.5.4.3 Rest of Middle East and Africa
  • 5.5.5 South America
    • 5.5.5.1 Brazil
    • 5.5.5.2 Argentina
    • 5.5.5.3 Rest of South America

6 Competitive Landscape

• 6.1 Market Concentration
• 6.2 Market Share Analysis
• 6.3 Company Profiles
  • 6.3.1 DMS Imaging
  • 6.3.2 Fujifilm Healthcare
  • 6.3.3 GE HealthCare
  • 6.3.4 Guangzhou Yueshen
  • 6.3.5 Mednova
  • 6.3.6 Hologic, Inc.
  • 6.3.7 MEDIKORS Co., Ltd.
  • 6.3.8 Medilink (France)
  • 6.3.9 Medonica Co., Ltd.
  • 6.3.10 Osteometer Meditech A/S
  • 6.3.11 OsteoSys Co., Ltd.
  • 6.3.12 Pinyuan Medical (Jiangsu) Co., Ltd.
  • 6.3.13 Shenzhen XRAY Electric Co., Ltd.
  • 6.3.14 Swissray International (Norland)
  • 6.3.15 XinGaoyi Medical Equipment Co., Ltd.

7 Market Opportunities & Future Outlook

• 7.1 White-space & unmet-need assessment